Skip to content
Publicly Available Published by De Gruyter March 1, 2012

Can nanotechnology potentiate photodynamic therapy?

  • Ying-Ying Huang , Sulbha K. Sharma , Tianhong Dai , Hoon Chung , Anastasia Yaroslavsky , Maria Garcia-Diaz , Julie Chang , Long Y. Chiang and Michael R. Hamblin EMAIL logo
From the journal Nanotechnology Reviews

Abstract

Photodynamic therapy (PDT) uses the combination of nontoxic dyes and harmless visible light to produce reactive oxygen species that can kill cancer cells and infectious microorganisms. Due to the tendency of most photosensitizers (PS) to be poorly soluble and to form nonphotoactive aggregates, drug-delivery vehicles have become of high importance. The nanotechnology revolution has provided many examples of nanoscale drug-delivery platforms that have been applied to PDT. These include liposomes, lipoplexes, nanoemulsions, micelles, polymer nanoparticles (degradable and nondegradable), and silica nanoparticles. In some cases (fullerenes and quantum dots), the actual nanoparticle itself is the PS. Targeting ligands such as antibodies and peptides can be used to increase specificity. Gold and silver nanoparticles can provide plasmonic enhancement of PDT. Two-photon excitation or optical upconversion can be used instead of one-photon excitation to increase tissue penetration at longer wavelengths. Finally, after sections on in vivo studies and nanotoxicology, we attempt to answer the title question, “can nanotechnology potentiate PDT?”


Corresponding author

Received: 2011-10-28
Accepted: 2012-1-12
Published Online: 2012-03-01
Published in Print: 2012-03-01

©2012 by Walter de Gruyter Berlin Boston

Downloaded on 23.4.2024 from https://www.degruyter.com/document/doi/10.1515/ntrev-2011-0005/html
Scroll to top button